A phase I trial of AB001
Latest Information Update: 09 May 2024
At a glance
- Drugs 212Pb-NG001 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 09 May 2024 New trial record
- 07 May 2024 According to an ARTBIO media release, the company has entered into an agreement with Nucleus RadioPharma Inc. (Nucleus), to manufacture AB001 for its planned phase I and phase II trials.